Product Description: Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Moore KN, et al. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 1;35(10):1112-1118.
CAS Number: 1453084-36-0
Molecular Weight: N/A
Compound Purity: 99.76
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Antifolate